



Supplementary Fig. S6

A




**Supplementary Fig. S6**

**B**




Supplementary Fig. S7

A




**Supplementary Fig. 7**

**B**



**Supplementary Fig. S7**

**C**



Supplementary Table S4

IC50 ( $\mu$ M) $\pm$ SD	hCol1		hCol2	
	TiD	2D	TiD	2D
5FU	>25	9 $\pm$ 1.12	3.25 $\pm$ 0.5	2.5 $\pm$ 0.78
Irinotecan	>25	5.75 $\pm$ 0.9	0.3 $\pm$ 0.07	0.65 $\pm$ 0.1
Oxaliplatin	>25	3.25 $\pm$ 1.25	>25	0.9 $\pm$ 0.43
SN38	0.45 $\pm$ 0.19	0.08 $\pm$ 0.005	0.07 $\pm$ 0.01	0.05 $\pm$ 0.01

Supplementary Table S5

IC50 ( $\mu$ M) $\pm$ SD	hOVR1		hOVR2	
	TiD	2D	TiD	2D
5FU	<b>10 ± 1.73</b>	<b>1.5 ± 0.5</b>	<b>3.5 ± 0.52</b>	<b>4 ± 0.38</b>
Irinotecan	<b>4 ± 0.8</b>	<b>1 ± 0.21</b>	<b>15.75 ± 3.78</b>	<b>1 ± 0.15</b>
Oxaliplatin	<b>4.25 ± 0.25</b>	<b>8.5 ± 1</b>	<b>&gt;100</b>	<b>11 ± 0.3</b>
Cisplatin	<b>10.25 ± 3.19</b>	<b>8.5 ± 1.3</b>	<b>&gt;100</b>	<b>18 ± 1.75</b>
Carboplatin	<b>30 ± 3.22</b>	<b>5 ± 0.721</b>	<b>&gt;100</b>	<b>77 ± 10.64</b>